コンテンツへスキップ
Merck

M-136

Supelco

メトトレキサート 溶液

1.0 mg/mL in methanol with 0.1N NaOH, ampule of 1 mL, certified reference material, Cerilliant®

ログイン組織・契約価格を表示する


About This Item

実験式(ヒル表記法):
C20H22N8O5
CAS番号:
分子量:
454.44
MDL番号:
UNSPSCコード:
41116107
PubChem Substance ID:

グレード

certified reference material

品質水準

形状

liquid

特徴

Snap-N-Spike®/Snap-N-Shoot®

包装

ampule of 1 mL

メーカー/製品名

Cerilliant®

濃度

1.0 mg/mL in methanol with 0.1N NaOH

テクニック

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

アプリケーション

pharmaceutical (small molecule)

フォーマット

single component solution

保管温度

−20°C

SMILES記法

O=C(C1=CC=C(N(C)CC2=NC3=C(N=C2)N=C(N)N=C3N)C=C1)NC(C(O)=O)CCC(O)=O

InChI

1S/C20H22N8O5/c1-28(9-11-8-23-17-15(24-11)16(21)26-20(22)27-17)12-4-2-10(3-5-12)18(31)25-13(19(32)33)6-7-14(29)30/h2-5,8,13H,6-7,9H2,1H3,(H,25,31)(H,29,30)(H,32,33)(H4,21,22,23,26,27)

InChI Key

FBOZXECLQNJBKD-UHFFFAOYSA-N

詳細

A Certified Spiking Solution® for use in therapeutic drug monitoring (TDM) analyses by HPLC or LC/MS. Used in the treatment of cancer and autoimmune diseases, methotrexate is an antimetabolite and antifolate drug monitored by clinical labs to ensure patients remain within the drug′s therapeutic range. The Snap-N-Spike® format allows laboratories to eliminate weighing operations of hazardous substances such as methotrexate, significantly reducing occupational exposure hazards related to handling of acutely toxic powders, and provides the ability to spike into their matrix of choice just before use.

アプリケーション


  • Pharmacokinetic analysis: Methotrexate solution is employed in advanced pharmacokinetic studies using UV-Vis spectrophotometric and colorimetric methods. This application facilitates precise quantification in plasma and tissue, crucial for evaluating drug distribution and effectiveness in cancer treatments (Febrianti et al., 2024).

  • Toxicity and safety monitoring: Observational studies utilize Methotrexate solution to investigate root causes of medication errors and manage toxicity in elderly patients. This research supports safer clinical practices by identifying risk factors and improving patient safety protocols (Bisht et al., 2024).

  • Nephrotoxicity prevention: Research on Methotrexate solution examines hydration strategies to mitigate nephrotoxicity, enhancing therapeutic outcomes. This study is pivotal in optimizing Methotrexate use in clinical settings, ensuring higher safety and efficacy for patients undergoing chemotherapy (Hasanpour et al., 2024).


法的情報

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
CERTIFIED SPIKING SOLUTION is a registered trademark of Cerilliant Corporation
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

ピクトグラム

FlameCorrosionSkull and crossbonesHealth hazard

シグナルワード

Danger

危険有害性の分類

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - Met. Corr. 1 - STOT SE 1

保管分類コード

3 - Flammable liquids

WGK

WGK 2

引火点(°F)

51.8 °F - closed cup

引火点(℃)

11 °C - closed cup


適用法令

試験研究用途を考慮した関連法令を主に挙げております。化学物質以外については、一部の情報のみ提供しています。 製品を安全かつ合法的に使用することは、使用者の義務です。最新情報により修正される場合があります。WEBの反映には時間を要することがあるため、適宜SDSをご参照ください。

消防法

第4類:引火性液体
アルコール類
危険等級II

労働安全衛生法名称等を表示すべき危険物及び有害物

名称等を表示すべき危険物及び有害物

労働安全衛生法名称等を通知すべき危険物及び有害物

名称等を通知すべき危険物及び有害物

Jan Code

M-136-1ML:4.548173318394E12


試験成績書(COA)

製品のロット番号・バッチ番号を入力して、試験成績書(COA) を検索できます。ロット番号・バッチ番号は、製品ラベルに「Lot」または「Batch」に続いて記載されています。

以前この製品を購入いただいたことがある場合

文書ライブラリで、最近購入した製品の文書を検索できます。

文書ライブラリにアクセスする

この製品を見ている人はこちらもチェック

Joshua F Baker et al.
Annals of the rheumatic diseases, 73(11), 1968-1974 (2013-08-02)
To determine if early MRI measures predict X-ray progression at 1 and 2 years in a large RA trial cohort. This study included 256 methotrexate (MTX)-naïve RA patients from a randomised placebo-controlled trial of golimumab (GO-BEFORE). MRIs of wrist and 2nd-5th
Josef S Smolen et al.
Lancet (London, England), 383(9914), 321-332 (2013-10-31)
Biological agents offer good control of rheumatoid arthritis, but the long-term benefits of achieving low disease activity with a biological agent plus methotrexate or methotrexate alone are unclear. The OPTIMA trial assessed different treatment adjustment strategies in patients with early
Daniel H Solomon et al.
The American journal of medicine, 126(8), 730-730 (2013-07-28)
Elevated tumor necrosis factor (TNF)-α likely contributes to the excess cardiovascular risk observed in rheumatoid arthritis. We compared the cardiovascular risk in rheumatoid arthritis patients starting a TNF-α blocking agent versus a nonbiologic disease-modifying antirheumatic drug (nbDMARD). Subjects with rheumatoid
James R O'Dell et al.
The New England journal of medicine, 369(4), 307-318 (2013-06-13)
Few blinded trials have compared conventional therapy consisting of a combination of disease-modifying antirheumatic drugs with biologic agents in patients with rheumatoid arthritis who have active disease despite treatment with methotrexate--a common scenario in the management of rheumatoid arthritis. We
Richard Conway et al.
Arthritis & rheumatology (Hoboken, N.J.), 66(4), 803-812 (2014-04-24)
Methotrexate has shown efficacy for the treatment of several diseases, especially rheumatoid arthritis (RA). Methotrexate has also been implicated as a causative agent in interstitial lung disease. Patients with RA may develop pulmonary manifestations of their disease and are at

ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.

製品に関するお問い合わせはこちら(テクニカルサービス)